Cost-effectiveness of Prophylactic Zika Virus Vaccine in the Americas

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Shoukat, Affan ; Vilches, Thomas ; Moghadas, Seyed M.
• Description:
  Zika virus remains a major public health concern because of its association with microcephaly and other neurologic disorders in newborns. A prophylactic vaccine has the potential to reduce disease incidence and eliminate birth defects resulting from prenatal Zika virus infection in future outbreaks. We evaluated the cost-effectiveness of a Zika vaccine candidate, assuming a protection efficacy of 60%-90%, for 18 countries in the Americas affected by the 2015-2017 Zika virus outbreaks. Encapsulating the demographics of these countries in an agent-based model, our results show that vaccinating women of reproductive age would be very cost-effective for sufficiently low (<$16) vaccination costs per recipient, depending on the country-specific Zika attack rate. In all countries studied, the median reduction of microcephaly was >75% with vaccination. These findings indicate that targeted vaccination of women of reproductive age is a noteworthy preventive measure for mitigating the effects of Zika virus infection in future outbreaks.
• Subjects:
  Agent-based Simulations Americas Cost-effectiveness Cost-effectiveness Of Prophylactic Zika Virus Vaccine In The Americas Microcephaly Research Vaccination Viruses Zika Virus
• Source:
  Emerg Infect Dis. 25(12):2191-2196
• Pubmed ID:
  31742512
• Pubmed Central ID:
  PMC6874261
• Document Type:
  Journal Article
• Volume:
  25
• Issue:
  12
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:0c9de5406deea5757f7ad30022040112fcb81b2301b7cb952f0a8aa5de6ab4c2
• Download URL:
  https://stacks.cdc.gov/view/cdc/83284/cdc_83284_DS1.pdf
• File Type:
  [PDF - 1.03 MB ]